Antidiabetic drugs present and future: will improving insulin resistance benefit cardiovascular risk in type 2 diabetes mellitus? (Q34112906)

31 July 2017

1 reference

title

Antidiabetic drugs present and future: will improving insulin resistance benefit cardiovascular risk in type 2 diabetes mellitus? (English)

1 reference

31 July 2017

1 reference

1 reference

0 references

1 reference

Campbell IW

1

1 reference

PubMed ID

11129120

31 July 2017

language of work or name

1 reference

1 November 2000

1 reference

31 July 2017

1 reference

31 July 2017

60

1 reference

31 July 2017

5

1 reference

31 July 2017

1017-1028

1 reference

https://scigraph.springernature.com/pub.10.2165/00003495-200060050-00004

31 July 2017

0 references

cites work

Thiazolidinediones: a new class of antidiabetic drugs

1 reference

12 December 2020

Effect of repaglinide addition to metformin monotherapy on glycemic control in patients with type 2 diabetes.

1 reference

12 December 2020

Intensive insulin therapy prevents the progression of diabetic microvascular complications in Japanese patients with non-insulin-dependent diabetes mellitus: a randomized prospective 6-year study

1 reference

12 December 2020

The effect of glibenclamide and metformin on serum lipoproteins in type 2 diabetes

1 reference

12 December 2020

The effect of long-term intensified insulin treatment on the development of microvascular complications of diabetes mellitus

1 reference

12 December 2020

Metformin hydrochloride: an antihyperglycemic agent.

1 reference

12 December 2020

1 reference

12 December 2020

Serum insulin and incident coronary heart disease in middle-aged British men.

1 reference

12 December 2020

Improving the adverse cardiovascular prognosis of type 2 diabetes

1 reference

12 December 2020

Rationale for the use of insulin therapy alone as the pharmacological treatment of type 2 diabetes

1 reference

12 December 2020

Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group

1 reference

12 December 2020

Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group

1 reference

12 December 2020

1 reference

12 December 2020

Re-evaluation of a biguanide, metformin: mechanism of action and tolerability

1 reference

12 December 2020

Effect of metformin on carbohydrate and lipoprotein metabolism in NIDDM patients

1 reference

12 December 2020

Effects of metformin on insulin resistance, risk factors for cardiovascular disease, and plasminogen activator inhibitor in NIDDM subjects. A study of two ethnic groups.

1 reference

12 December 2020

Hyperinsulinemia as an independent risk factor for ischemic heart disease.

1 reference

12 December 2020

Haemodynamic and other effects of sulphonylurea drugs on the heart

1 reference

12 December 2020

Effects of metformin on glucose, insulin and lipid metabolism in patients with mild hypertriglyceridaemia and non-insulin dependent diabetes by glucose tolerance test criteria

1 reference

12 December 2020

Troglitazone, an insulin action enhancer, improves metabolic control in NIDDM patients. Troglitazone Study Group.

1 reference

12 December 2020

United Kingdom Prospective Diabetes Study 17: a 9-year update of a randomized, controlled trial on the effect of improved metabolic control on complications in non-insulin-dependent diabetes mellitus.

1 reference

12 December 2020

Glimepiride. A review of its use in the management of type 2 diabetes mellitus

1 reference

12 December 2020

Insulin and atheroma. 20-yr perspective

1 reference

12 December 2020

Comparative tolerability profiles of oral antidiabetic agents

1 reference

12 December 2020

The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. The Diabetes Control and Complications Trial Research Group

1 reference

12 December 2020

Metformin-associated lactic acidosis: a rare or very rare clinical entity?

1 reference

12 December 2020

Cardiovascular effects of sulphonylurea derivatives.

1 reference

12 December 2020

Prevention of complications in non-insulin-dependent diabetes mellitus (NIDDM).

1 reference

12 December 2020

Mechanism of metformin action in obese and lean noninsulin-dependent diabetic subjects.

1 reference

12 December 2020

Role of sulfonylureas in non-insulin-dependent diabetes mellitus: Part I--"The pros".

1 reference

12 December 2020

Troglitazone: a review of its use in the management of type 2 diabetes mellitus

1 reference

12 December 2020

Insulin resistance and thrombosis: a cardiologist's view

1 reference

12 December 2020

Glyburide in non-insulin-dependent diabetes: an update

1 reference

12 December 2020

Pathophysiology of vascular disease in diabetes: effects of gliclazide

1 reference

12 December 2020

A study of the effects of hypoglycemia agents on vascular complications in patients with adult-onset diabetes. VI. Supplementary report on nonfatal events in patients treated with tolbutamide

1 reference

12 December 2020

10.2165/00003495-200060050-00004

Identifiers

DOI

1 reference

PubMed ID

11129120

Dimensions Publication ID

31 July 2017

0 references

1 reference

PubMed ID

11129120